Cure disease – Heiki http://heiki.org/ Thu, 29 Apr 2021 08:35:46 +0000 en-US hourly 1 https://wordpress.org/?v=5.7.1 https://heiki.org/wp-content/uploads/2021/04/cropped-icon-32x32.png Cure disease – Heiki http://heiki.org/ 32 32 Core One Labs signs definitive agreement to acquire OTC markets from Akome Biotech: CLABF https://heiki.org/core-one-labs-signs-definitive-agreement-to-acquire-otc-markets-from-akome-biotech-clabf/ https://heiki.org/core-one-labs-signs-definitive-agreement-to-acquire-otc-markets-from-akome-biotech-clabf/#respond Thu, 29 Apr 2021 08:00:00 +0000 https://heiki.org/core-one-labs-signs-definitive-agreement-to-acquire-otc-markets-from-akome-biotech-clabf/ VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company“), A Life Sciences Biotechnology Research & Development Company Focused On Advancing Psychedelic Drugs In The Market, Is Happy To Announce It Has Entered A Definitive Share Purchase Agreement (the”Final agreement”), As of […]]]>


VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company“), A Life Sciences Biotechnology Research & Development Company Focused On Advancing Psychedelic Drugs In The Market, Is Happy To Announce It Has Entered A Definitive Share Purchase Agreement (the”Final agreement”), As of April 23, 2021, pursuant to which it will acquire all of the outstanding share capital of Akome Biotech Ltd. (“Akome”). The Akome acquisition places the company at the forefront of the development of psychedelic drugs for neurological diseases and mental disorders.

Akome CEO, Dr Santiago Ferro has extensive experience leading clinical research teams and has been involved in all aspects of a start-up and the product lifecycle: from product development clinical and regulatory strategies, sales and marketing opportunities with companies such as Sanofi Pasteur, Novartis and Glaxo Smith Klein. Dr Fadia Saad is co-founder of Akome and the inventor of its patents.

Akome’s goal is to develop safe and effective treatments for stroke, Alzheimer’s disease, depression and Parkinson’s disease. 1The global stroke management market was worth $ 22.5 billion in 2016 and is expected to reach $ 36.7 billion by 2023, with a CAGR of 7.1%. 287% of strokes are ischemic strokes. An ischemic stroke occurs when blood flow through the artery that supplies oxygen-rich blood to the brain is blocked. The treatment currently available for acute ischemic stroke is the administration of the thrombolytic agent, tissue plasminogen activator.

3The global Alzheimer’s disease therapeutics market is expected to reach USD 13.57 billion by 2027, up from USD 7.42 billion in 2019, with a substantial CAGR of 9.2% throughout the forecast period . There is currently no pharmacological treatment available today to slow or stop the damage and destruction of neurons responsible for Alzheimer’s disease. No drug has been specifically approved by the FDA to treat the behavioral and psychiatric symptoms that may develop in the moderate and severe stages of Alzheimer’s dementia.

4Depression affects more than 264 million people. It is a disabling disorder, responsible for most of the 800,000 annual suicides. In 2008, the WHO ranked major depression as the third leading cause of the disease burden globally and projected it to be number one by 2030.

5Parkinson’s disease is a global burden and has more than doubled over the past decade. Almost a million people live with Parkinson’s disease in the United States and 10 million people worldwide. The Parkinson’s disease treatment market was valued at $ 3.99 billion in 2016, and by 2022 it is expected to reach $ 5.69 billion. Currently, there is no cure for Parkinson’s disease, but there are therapies available to relieve the symptoms. Levodopa is the main drug used to make dopamine to replenish the brain by decreasing the supply of dopamine mimicking in the brain.

Joel Shacker, CEO of the company, said: “This acquisition will place us at the forefront of research into the use of psychedelics for the treatment of multiple illnesses, elevating our company’s portfolio to be comparable to that of the largest company in the industry. Akome’s seasoned management team has experience taking products from their developmental stage to commercialization. Their current pipeline of four interim composition patents looks forward to expanding into commercial products to help people with Alzheimer’s disease, stroke, Parkinson’s disease and depression, opening us up to to a multi-billion dollar processing market.

In consideration for all of Akome’s outstanding share capital, the Company is required to issue 3,500,000 common shares to existing Akome shareholders. After issuance, the shares will be subject to the conditions of a pooling agreement, during which they cannot be transferred or traded without the prior consent of the Company.

The company is independent from Akome and each of its shareholders. The Acquisition will not constitute a fundamental change to the Company and will not result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Stock Exchange.

About Core One Labs Inc.

Core One is a life science biotechnology and technology research company focused on commercializing psychedelic drugs through novel delivery systems and assisted psychedelic psychotherapy. Core One has developed a patent-pending thin-film oral tape (the “TechnologyWhich dissolves instantly when placed in the mouth and delivers organic molecules in precise amounts into the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also has an interest in medical clinics which maintain a combined database of over 275,000 patients. Thanks to these clinics, the integration of its intellectual property, the R&D related to psychedelic treatments and new pharmacotherapies, the Company intends to obtain research regulatory approval for the advancement of treatments derived from psychedelics for mental health disorders. .

Core One Labs Inc.
Joel shacker
Chief executive officer

FOR MORE INFORMATION PLEASE CONTACT:
info@core1labs.com
1-866-347-5058

Disclaimer:

The Canadian Stock Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the contents of this press release.

The information contained in this press release contains forward-looking statements based on assumptions as of the date of this press release. These statements reflect the current estimates, beliefs, intentions and expectations of management. These are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the control of the Company. These factors include, among others: risks and uncertainties associated with the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the company does not undertake to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and possession of substances under Controlled Drugs and Substances Act (Canada) without prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One has no direct or indirect involvement in the illegal sale, production or distribution of psychedelics in the jurisdictions in which it operates. While Core One believes that psychedelics can be used to treat certain medical conditions, it does not advocate legalizing psychedelics for recreational purposes. Core One does not deal with psychedelics except in clinical and laboratory trials conducted under approved regulatory frameworks.


1 https://www.alliedmarketresearch.com/stroke-diagnostics-and-therapeutics-market
2 https://www.cdc.gov/stroke/types_of_stroke.htm
3 https://www.medgadget.com/2021/01/alzheimers-therapeutics-market-to-reach-usd-13-57-billion-by-2027-size-share-industry-analysis-and-global-forecast- at-2027.html
4 https://www.who.int/news-room/fact-sheets/detail/depression
5 https://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html



Source link

]]>
https://heiki.org/core-one-labs-signs-definitive-agreement-to-acquire-otc-markets-from-akome-biotech-clabf/feed/ 0
All-State Academic: Central Region https://heiki.org/all-state-academic-central-region/ https://heiki.org/all-state-academic-central-region/#respond Sun, 25 Apr 2021 07:58:10 +0000 https://heiki.org/all-state-academic-central-region/ Lucy brooner Ankeny ACT Score: 34 GPA: 4.423 University: Undecided Major: Biomedical genius What are your life goals? The scientific world has always been a huge area of ​​interest for me. In 2019, I started scuba diving training, becoming a certified open water diver, and I hope to continue scuba diving throughout my life. I […]]]>


Lucy brooner

Ankeny

ACT Score: 34

GPA: 4.423

University: Undecided

Major: Biomedical genius

What are your life goals? The scientific world has always been a huge area of ​​interest for me. In 2019, I started scuba diving training, becoming a certified open water diver, and I hope to continue scuba diving throughout my life. I would love to train for even more certifications like night diving and dry suit diving in the future. I currently want to specialize in biomedical engineering, although I don’t know where. I would love to pursue a career in medical research and have often considered becoming a doctor myself. I want to help as many people as possible, whether I’m working with them directly as a doctor or indirectly doing behind-the-scenes research. My ultimate career goal is simply to be satisfied with my job and to enjoy working in my field.



Source link

]]>
https://heiki.org/all-state-academic-central-region/feed/ 0
KC man diagnosed with ALS will be part of highly competitive medical trial https://heiki.org/kc-man-diagnosed-with-als-will-be-part-of-highly-competitive-medical-trial/ https://heiki.org/kc-man-diagnosed-with-als-will-be-part-of-highly-competitive-medical-trial/#respond Fri, 23 Apr 2021 02:16:00 +0000 https://heiki.org/kc-man-diagnosed-with-als-will-be-part-of-highly-competitive-medical-trial/ “Today I consider myself the luckiest man on the planet.” In 1939, those words were spoken by Yankees first baseman Lou Gehrig. His speech grabbed the nation, announcing an early retirement from gambling after a fatal diagnosis of ALS. “I might have had a bad break, but I have so much to live for,” Gehrig […]]]>


“Today I consider myself the luckiest man on the planet.” In 1939, those words were spoken by Yankees first baseman Lou Gehrig. His speech grabbed the nation, announcing an early retirement from gambling after a fatal diagnosis of ALS. “I might have had a bad break, but I have so much to live for,” Gehrig said. In the digital age, awareness of disease is more like the challenge of the ice bucket. But behind the shocking laughter and splash, there are struggles with a disease that still has few answers. For Scott Smith, fitness is a way of life. His passion for athletics, leading to the ownership of a personal training business in Kansas City. “Part of how I got here was being a high performing player, a goalscorer,” Smith said. “I think it’s a good thing.” After years of regulated schedules, a growing family, and growing success, it was one small change that sparked a major reveal. “I was interviewing a potential client when I noticed I was tripping over my words more than usual,” he said. Smith learned that he was one of 5,000 people in the United States diagnosed with ALS each year. The disease weakens the muscles and is currently incurable, with a life expectancy of three to five years. “The doctor gave us that diagnosis and then pretty much it was like, ‘I can’t tell you how long you’re going to live, I can’t tell you how it’s going to work out, I can’t tell you. any promising drug or treatment that will help you, ”said his wife, Jamie Smith. “I would say it was probably the worst day of our lives.” For patients like Smith, there is hope on the horizon. Treatments currently in trials have helped some reverse the deterioration enough to walk and even run again. But these trials are expensive and limited to less than 5% of patients. “There is reason to hope, but we don’t have access to it,” Smith said. “It’s so frustrating.” The Act for SLA bill, now about to be introduced in Washington, could change that by allocating $ 100 million annually to the cause. Kansas Senator Roger Marshall is leading the charge to pass the bill. “We will do our best to get it through during this Congress,” Marshall said. While opposing lawmakers declined an interview, we went to see a UMKC law professor who said the opposition likely comes down to the toll. “I imagine people concerned about fiscal responsibility might be like, ‘OK, this is a good cause, but what if we did this with every disease? “Said Professor Ann Marie Marciarille. Some doctors also fear, without FDA approval, that there are critical risks to consider:” What if the drug really suppresses the immune system? “Said Dr. Omar Jawdat, Associate Professor of Neurology at the University of Kansas Medical Center. Without Lou Gehrig’s platform, or an entourage of celebrities raising awareness through the ice bucket challenge, the search for a cure continues quietly . A few weeks ago, Smith received good news, acceptance in a highly competitive medical trial. “My wife and I said we would be the first generation to survive ALS,” he said. he said, “This essay makes it look like we could keep that promise.” Luckily, 29,000 ALS patients in the US are waiting right now Additional Links: To support Scott’s family: visit www.flexonals.com To help support the legislation: visit helpmayuri .com To take action Additional: visit https://iamals.org/action/fda-congressional-hearing/ For more: visit iamals.org.

“Today I consider myself the luckiest man on the planet.”

In 1939, those words were spoken by Yankees first baseman Lou Gehrig. His speech grabbed the nation, announcing an early retirement from gambling after a fatal diagnosis of ALS.

“I might have had a bad break, but I have so much to live for,” Gehrig said.

In the digital age, awareness of disease is more like the challenge of the ice bucket. But behind the shocking laughter and splash, there are struggles with a disease that still has few answers.

For Scott Smith, fitness is a way of life. His passion for athletics, leading to the ownership of a personal training business in Kansas City.

“Part of how I got here was being a high performing player, a goalscorer,” Smith said. “I think it’s a good thing.”

After years of regimented schedules, a growing family and growing success, it was one small change that sparked a major revelation.

“I was interviewing a potential client when I noticed I was tripping over my words more than usual,” he says.

Soon after, Smith learned he was one of 5,000 people in the United States diagnosed with ALS each year. The disease weakens the muscles and is currently incurable, with a life expectancy of three to five years.

“The doctor gave us that diagnosis and then pretty much it was like, ‘I can’t tell you how long you’re going to live, I can’t tell you how it’s going to work out, I can’t tell you. any promising drug or treatment that will help you, ”said his wife, Jamie Smith. “I would say it was probably the worst day of our lives.”

For patients like Smith, there is hope on the horizon. Treatments currently in trials have helped some reverse the deterioration enough to walk and even run again. But these trials are expensive and limited to less than 5% of patients.

“There is reason to hope, but we don’t have access to it,” Smith said. “It’s so frustrating.”

The Act for SLA bill, now about to be introduced in Washington, could change that by allocating $ 100 million annually to the cause.

Kansas Senator Roger Marshall is leading the charge to pass the bill.

“We’ll do our best to get it through at some point in this Congress,” Marshall said.

While opposing lawmakers declined an interview, we went to see a UMKC law professor who said the opposition likely comes down to the toll.

“I imagine people concerned about fiscal responsibility might be like, ‘OK, this is a good cause, but what if we did this with every disease? “Said Professor Ann Marie Marciarille.

Some doctors are also concerned, without FDA approval, that there are critical risks to consider.

“What if the drug really suppresses the immune system?” said Dr. Omar Jawdat, associate professor of neurology at the University of Kansas Medical Center.

Without Lou Gehrig’s platform, or an entourage of celebrities raising awareness through the ice bucket challenge, the search for a cure continues quietly.

A few weeks ago, Smith received good news, acceptance in a highly competitive medical trial.

“My wife and I said we would be the first generation to survive ALS,” he said. “This lawsuit gives the impression that we could keep that promise.”

Luckily, 29,000 ALS patients in the United States are waiting right now.

Additional links:

To support Scott’s family: visit www.flexonals.com

To help support the legislation: visit helpmayuri.com.

To take additional action: visit https://iamals.org/action/fda-congressional-hearing/

To find out more: visit iamals.org.



Source link

]]>
https://heiki.org/kc-man-diagnosed-with-als-will-be-part-of-highly-competitive-medical-trial/feed/ 0
Holbrook Life partners with the Wilkins Parkinson Coalition to raise awareness of Parkinson’s research https://heiki.org/holbrook-life-partners-with-the-wilkins-parkinson-coalition-to-raise-awareness-of-parkinsons-research/ https://heiki.org/holbrook-life-partners-with-the-wilkins-parkinson-coalition-to-raise-awareness-of-parkinsons-research/#respond Thu, 22 Apr 2021 23:48:00 +0000 https://heiki.org/holbrook-life-partners-with-the-wilkins-parkinson-coalition-to-raise-awareness-of-parkinsons-research/ ALPHARETTA, Georgia., April 22, 2021 / PRNewswire / – Holbrook Life, a collection of innovative active communities for adults, assisted living and memory care providers, is proud to announce a brand new partnership with Wilkin’s Parkinson Coalition. The aim is to raise awareness of all neurological disorders including Parkinson’s disease. One of our own residents, […]]]>


ALPHARETTA, Georgia., April 22, 2021 / PRNewswire / – Holbrook Life, a collection of innovative active communities for adults, assisted living and memory care providers, is proud to announce a brand new partnership with Wilkin’s Parkinson Coalition. The aim is to raise awareness of all neurological disorders including Parkinson’s disease. One of our own residents, Bill wilkins, who has lived with Parkinson’s for 15 years, and he says, “Education and awareness are mandatory ingredients in the journey to treatment. To date, the Wilkin’s Parkinsons Foundation has been able to secure more than $ 1 million in donations to raise awareness about Parkinson’s disease.

That’s why Mr. Wilkins is leveraging his career marketing expertise and philanthropic ability to create this partnership with Holbrook and Wilkins. In the past, he has successfully collaborated with the Michael J. Fox Foundation, the American Parkinson’s Disease Association and interacting with the Department of Movement Disorders in Neurology at Emory. For the month of April, in recognition of Parkinson’s Awareness Month, Holbrook Woodstock community staff all wear the stylized red tulip, with distinctive leaves shaped like “P” and “D” letters, it is emerging as the nationally recognized symbol of Parkinson’s awareness.

In all of our Holbrook Life communities, we are dedicated to service, inspiration and life to the fullest. Family, passion and faithful service are our pillars of philosophy. Well-being is at the heart of living life to the fullest. We have created equipment to support our residents, with a wellness center including hydrotherapy. Some of the benefits of hydrotherapy for neurological patients include improved balance and stability, lumbar stabilization, and increased endurance, strength and range of motion.

Giving back to the community is a priority at Holbrook Life. We know that partnering with organizations like Wilkins Parkinson’s Coalition will make a difference in finding a cure not only for Parkinson’s disease, but also for many other neurological conditions affecting our own residents and those in our community.

For more information on how you can participate in this call to action or to arrange interviews, please contact:

SOURCE Holbrook Life Communities

Related links

http://holbrooklife.com



Source link

]]>
https://heiki.org/holbrook-life-partners-with-the-wilkins-parkinson-coalition-to-raise-awareness-of-parkinsons-research/feed/ 0
Timely Drugs and Steroids, Not Remdesivir, Key to Covid Cure: Expert | Lucknow News https://heiki.org/timely-drugs-and-steroids-not-remdesivir-key-to-covid-cure-expert-lucknow-news/ https://heiki.org/timely-drugs-and-steroids-not-remdesivir-key-to-covid-cure-expert-lucknow-news/#respond Thu, 22 Apr 2021 23:26:00 +0000 https://heiki.org/timely-drugs-and-steroids-not-remdesivir-key-to-covid-cure-expert-lucknow-news/ Lucknow: Even though reports of people going from pillar to post to obtain drugs Remdesivir and Fabiflu for corona patients have increased, scientists, citing multiple research and studies, are of the opinion that clinical outcomes may not change using fabiflu or remdesivir. In the case of Remdesivir, it has been stated in some reports that […]]]>


Lucknow: Even though reports of people going from pillar to post to obtain drugs Remdesivir and Fabiflu for corona patients have increased, scientists, citing multiple research and studies, are of the opinion that clinical outcomes may not change using fabiflu or remdesivir. In the case of Remdesivir, it has been stated in some reports that it may at best reduce hospital stay because these drugs are antiviral.
Instead, people should opt for steroids along with other prescribed combinations to save vital organs like the lungs, heart, brain, and kidneys. Citing reports, Professor Ramji Upadhyaya, an expert on infectious diseases, said that in the first wave the symptoms were different from that in this wave. Then the symptoms did not appear until after the fourth or fifth day and the progression of the disease worsened after the fifth to sixth day, but now if you are not careful on the first day, it could seriously affect the patient. Timing is very important, he said.
Rather than wait for the RT-PCR report, which takes three to four days, you should have CBP, CRP, LDH and D-dimer blood tests if you have even minor symptoms or are surrounded by limbs. positive family at home. Professor Ram, from Agra, Uttar Pradesh, said and added that reports of these tests would arrive in a few hours.
Medications like steroids and colchicine should be taken immediately at a calibrated dose if reports show increased protein and inflammation. He said that it has been seen that steroids have shown a great impact in saving vital organs if the same has been taken on time. Explaining further the reason for the rush, Professor Ram said that suppose the house caught fire, instead of going into the cause of the fire, we will try to put out the fire first.
Likewise, CBP and CRP will show the level of inflammation and if it is high the first thing to do is reduce the same and this can be done by giving steroids in a calibrated dose, the results showed. , Professor Ram, who is said to be the chief scientist of Ohm Oncology, United States.
Previously, the level of inflammation had increased after the fifth or sixth day, but now it is seen that the level has jumped a great deal even on the first day and therefore the treatment protocol should be changed, he said. . Therefore, the first day steroid is a better way to save the lives of corona patients, said Professor Ram and added that among the steroids, dexamethasone and prednisolone can be administered.
He added that high-resolution CT scans alone would not help identify the infection, as a shadow or spots in the lungs could be due to environmental concerns and the same could be misunderstood as the Corona effect. Citing a study from King’s College London, Professor Ram, who is also a professor at the Plasma Bioscience Research Center (PBRC) / Applied Medicine Research Center, Kwangwoon University, Seoul, South Korea, further stated that he performed a biopsy of the infected body. by Corona and found that the lungs have solidified due to blood clotting.
If the Corona infection reaches the lungs, an anticoagulant should be given along with steroids to prevent the lungs from solidifying due to the coronavirus. However, the anticoagulant should not be low molecular weight heparin, which can induce thrombocytopenia, which is more common in women, especially in those on any hormone replacement therapy or in the pre- menopause. The chances of clotting are greater in high-risk patients than in patients over 45, Professor Ram added.



Source link

]]>
https://heiki.org/timely-drugs-and-steroids-not-remdesivir-key-to-covid-cure-expert-lucknow-news/feed/ 0
A brief but spectacular view of chronic disease https://heiki.org/a-brief-but-spectacular-view-of-chronic-disease/ https://heiki.org/a-brief-but-spectacular-view-of-chronic-disease/#respond Thu, 22 Apr 2021 22:15:33 +0000 https://heiki.org/a-brief-but-spectacular-view-of-chronic-disease/ Rivka Solomon: Before this interview, I was definitely nervous and anxious, but I spoke a lot in public. However, what is tricky about these kinds of interviews is that you never know when your brain is just going to fly away, and I won’t be able to remember what I mean. I will not be […]]]>


Rivka Solomon:

Before this interview, I was definitely nervous and anxious, but I spoke a lot in public.

However, what is tricky about these kinds of interviews is that you never know when your brain is just going to fly away, and I won’t be able to remember what I mean. I will not be able to formulate sentences.

When I was 21, two of my roommates and I all had mononucleosis at the same time. They got better in about a month, and I hardly ever got better. After a year of being bedridden, I had a few years of semi-remission, but it didn’t last. It all came back with a second infection, pneumonia, and I was sick for three decades.

They called it chronic mono, then chronic Epstein-Barr virus, then chronic fatigue syndrome. And now they call it ME / CFS, chronic fatigue syndrome of myalgic encephalomyelitis. Most of us just call it ME

We are up to two and a half million in the United States with ME, 24 million in the world. We have no cure, no cure, and people can be sick and disabled for decades, often bedridden like me, some unable to take care of themselves or feed themselves; 80% of people with ME got it after a viral or bacterial infection like me, and 75% of us are women.

I might look vibrant and full of life right now, but what’s going on is that a lot of us with ME, all of us with ME have post-stress discomfort. It’s called PEM. And that means that after doing anything that requires energy production, we will often collapse. We have a disproportionate return on investment.

So after doing this interview with you, I might find myself bedridden and unable to move, literally. When you ME, it affects absolutely every dimension of your life. Many of us, our families and our friends do not believe that we are really sick. It is a terribly lonely existence.

Right now, there are millions of people contracting COVID-19 from the coronavirus, and some are not getting better. They stay sick with what’s called a long COVID. Many people with long-term COVID will likely be eligible for a diagnosis of ME after six months of illness because they have many of the same symptoms as we do.

But something really beautiful came out of it all. The ME community and long-standing COVID communities are helping each other. It’s beautiful to see that. It is as if the elders help the newbies, but the newbies have a lot more political influence and also help us.

One of the issues that we have had as a community is that there has been a faction of the medical establishment that has come up with and propagated the myth that this is not a real disease, it is actually a psychological state.

So, for example, in the 1980s, “Newsweek” had a headline on their front – they had a cover – sorry – as you can see my brain is starting to disappear, right? You can see this happening here.

Even now, as I do this interview with you, I can feel the brain fog taking over. And I no longer remember your question, and I no longer remember the beginning of my sentence. I don’t remember the point I’m trying to make.

The only thing I want people back home to take away is to believe someone when they tell you how they feel. Don’t reject them. Do not neglect them. Believe them and have compassion.

My name is Rivka Solomon, and this is my brief but dramatic take on advocating for people with chronic illnesses.



Source link

]]>
https://heiki.org/a-brief-but-spectacular-view-of-chronic-disease/feed/ 0
Do psychiatrists treat illnesses? https://heiki.org/do-psychiatrists-treat-illnesses/ https://heiki.org/do-psychiatrists-treat-illnesses/#respond Thu, 22 Apr 2021 21:48:56 +0000 https://heiki.org/do-psychiatrists-treat-illnesses/ Of the many ducks directed at psychiatry in the late 20th century, one of the most persistent was the claim that psychiatric disorders are never included in pathology textbooks. For example, in 1998, a professor of psychology wrote confidently: “If ‘mental illness’ is really a disease of the brain, it would be listed as such […]]]>


Of the many ducks directed at psychiatry in the late 20th century, one of the most persistent was the claim that psychiatric disorders are never included in pathology textbooks. For example, in 1998, a professor of psychology wrote confidently: “If ‘mental illness’ is really a disease of the brain, it would be listed as such in standard pathology textbooks. It is not listed as a brain disease because it does not meet the nosological criteria of classification of diseases. “1

However, as I explained in an article published over 13 years ago,2 psychiatrists do not need to assert that the serious conditions we treat are diseases of the brain – only that conditions like schizophrenia and bipolar disorder represent a bona fide illness and that the term disease is most usefully understood as a set of very distressing and dysfunctional conditions of individuals, not just their brains.

Brains, of course, can show cellular pathology, but this is only the physical substrate of some pathological conditions.3 Cellular pathology is not a disease in the holistic and experiential sense that so deeply concerns physicians and their patients. Indeed, those who argue that the disease necessarily requires known structural abnormalities or cellular pathology should reflect on this sweeping statement in the 8th edition of Harrison’s Principles of Internal Medicine: “The purpose of the clinical method is to collect precise data concerning all the diseases to which human beings are subjected; namely, all the conditions which limit life in its powers, its enjoyment and its duration. “4

The editors go on to state that “the primary and traditional goals of the physician are utilitarian – the prevention and treatment of disease and the alleviation of suffering, whether bodily or mental”.4

In arguing thus, the editors implicitly invoked the 12th century physician-philosopher Moses Maimonides, who taught that “a doctor does not treat disease; rather, he is treating a sick person.5

Why should we care what the pathology textbooks say?

In my 2008 article, I presented several examples of pathology or neuropathology textbooks that recognized schizophrenia as a true form of the disease.6 In this article, I can update the list of pathology texts that clearly recognize schizophrenia as an instantiation of the disease. To be clear: it is quite different than claiming that schizophrenia is a single and distinct disease like, for example, pneumococcal pneumonia; this is certainly not the case.

Schizophrenia has long been recognized as a form of illness. Eugen Bleuler, MD, referred to “schizophrenias” (plural) over 100 years ago, and most scholars today view schizophrenia as a heterogeneous group of related disease entities.7 In addition, I use schizophrenia as a sort of proxy for serious mental illness, which can include bipolar disorder, post-traumatic stress disorder, autism, and several other conditions.

But why bother with this exercise in the first place? I think the question is very relevant in relation to the place occupied by psychiatry in the general field of medicine. The voices of anti-psychiatry intend to extract and exclude psychiatry from the realm of legitimate medical specialties, and they attempt to do so by denying that the conditions we are dealing with are characterized as genuine. disease or illness.8 Antipsychiatry invokes the putative authority of pathology texts to make its arguments, as if only pathologists could fathom the true nature of the disease. This deification of pathology must be seen as the triumph of scientism over science.

Pathology texts that recognize schizophrenia

While some pathology textbooks recognize psychiatric conditions such as schizophrenia as legitimate examples of illness, the case for antipsychiatry is drastically weakened. With that in mind, here are some updated entries from several pathology texts that recognize schizophrenia as a bona fide illness.

Robbins and Cotran Pathology Review: “Multifactorial inheritance does not have a well-defined risk of recurrence, but tends to run in families and is more characteristic for diseases such as diabetes or schizophrenia.”9

Practical surgical neuropathology: a diagnostic approach: “Human disease is increasingly appreciated as having an underlying genetic basis. This is especially true of neurological diseases, where genetic variants have been shown to increase risk or directly cause schizophrenia, autism spectrum disorders, and neurodegenerative diseases. “ten

Pathology: oxidative stress and dietary antioxidants: “Schizophrenia is a mental illness that includes positive, negative and cognitive symptoms. Hyperactive dopaminergic signal transduction in the mesolimbic system and OS [oxidative stress] among other factors, are associated with the neurobiology of schizophrenia. “11

Pathology manual: “There are no specific biochemical or morphological changes in common acquired mental illnesses due to mental stress, tension, anxiety, overwork and frustration; for example, depression, schizophrenia. “12

Note how this last sentence belies 3 cardinal (and false) principles of antipsychiatry: 1) true illness must be physical or bodily, and not mental; 2) actual illnesses must exhibit specific biochemical or morphological deviations from normal; and 3) schizophrenia and depression are not real illnesses. Whether the author takes mental illnesses for granted due to mental stress is certainly subject to review and refinement, but that is not an obstacle to considering schizophrenia as a type of illness.

Final thoughts

To be clear: the reality of psychiatric illness does not depend on what the textbooks include or do not include as illnesses. This reality manifests itself every day in the suffering and incapacity of our patients.13 Nonetheless, it is important that psychiatry, as a profession, correct the misrepresentation of its ill-informed critics – especially those who seek to marginalize psychiatry by denying the reality of the illnesses that plague our patients.

Dr Pies is Professor Emeritus of Psychiatry and Lecturer in Bioethics and Humanities, SUNY Upstate Medical University; Clinical Professor of Psychiatry, Tufts University School of Medicine; and editor emeritus of Psychiatric timeTM (2007-2010).

The references

1. Schaler J. Mental health parity. Philadelphia Inquirer. August 22, 1998: A12. Accessed April 22, 2021.

2. Pies R. Psychiatric diagnosis and the pathologist’s perspective on schizophrenia. Psychiatry (Edgmont). 2008; 5 (7): 62-65.

3. Virchow R. Introduction. In: Rather LJ, trans. Disease, life and man: selected essays by Rudolf Virchow. Stanford University Press; 1958.

4. Isselbacher K. Introduction. Harrison’s Principles of Internal Medicine, 8th ed. GW Thorn et al., Eds. McGraw-Hill; 1977.

5. Kottek SS. To become an accomplished doctor: Maimonides against Galen. Rambam Maimonides Med J. 2011; 2 (4): e0060.

6. Esri MM, Morris JH, eds. The neuropathology of dementia. Cambridge University Press; 1997.

7. Alnæs D, Kaufmann T, van der Meer D, et al. Cerebral heterogeneity in schizophrenia and its association with polygenic risk. JAMA Psychiatry. 2019; 76 (7): 739-748.

8. Benning TB. No mental illness? Critical reflections on the major ideas and legacy of Thomas Szasz. BJPsych Bull. 2016; 40 (6): 292-295.

9. Klatt EC, Kumar V. Diseases of infancy and childhood. In: Robbins and Cotran, eds. Pathology examination, 4th ed. Saunders; 2014: 130-146.

10. Solomon DA. Integration of molecular diagnostics with surgical neuropathology. In: Perry A, Bratt DJ, eds. Practical surgical neuropathology: a diagnostic approach, 2nd edition. Elsevier; 2017: 71-90.

11. M. Moretti, Mat 1 Rodrigues. Ascorbic acid as an antioxidant and applications to the central nervous system. In: Preedy V, ed. Pathology: oxidative stress and dietary antioxidants. Academic press; 2020: 159-168.

12. Mohan H. Cellular adaptation and cell injury. Pathology manual + rapid pathology review, 8th edition. Jaypee Brothers Medical Publishing; 2018: 33-69.

13. Pies RW. What is “disease”? Implications of chronic fatigue syndrome. Psychiatric time. March 2, 2015. Accessed April 22, 2021.



Source link

]]>
https://heiki.org/do-psychiatrists-treat-illnesses/feed/ 0
Is CBD Good For Anxiety And Stress Relief? https://heiki.org/is-cbd-good-for-anxiety-and-stress-relief/ https://heiki.org/is-cbd-good-for-anxiety-and-stress-relief/#respond Thu, 22 Apr 2021 20:07:00 +0000 https://heiki.org/is-cbd-good-for-anxiety-and-stress-relief/ USA, April 22, 2021 /EINPresswire.com/ – It seems like cannabidiol (CBD) is everywhere these days. And it’s not just something young people use. In fact, industry reports show that people with arthritis are among the top buyers of CBD, and research suggests that people with arthritis are very interested in using it for pain relief. […]]]>

USA, April 22, 2021 /EINPresswire.com/ – It seems like cannabidiol (CBD) is everywhere these days. And it’s not just something young people use.

In fact, industry reports show that people with arthritis are among the top buyers of CBD, and research suggests that people with arthritis are very interested in using it for pain relief. people also asked, Does CBD Help Fight Anxiety?

What is CBD?
CBD is a chemical extracted from hemp, a variety of cannabis plant related to marijuana. CBD doesn’t get people high, but it can cause drowsiness. Still, some people with arthritis who have tried CBD say they experienced noticeable pain relief, better sleep, and reduced anxiety. As good as

Is it safe to use?
No serious problems have been associated with moderate doses of CBD.

Is it legal?
Clearance laws can eventually be created, but currently CBD can be purchased in almost any state and online.
If you decide to try it
● Understand that CBD can be taken orally, inhaled (CBD Oil) or applied to the skin (CBD Cream).
● Look for products made in the United States with local ingredients.
● Avoid companies that claim their products cure disease.
● Do not use CBD as a substitute for disease-modifying anti-rheumatic drugs (DMARDs). These important drugs help prevent permanent joint damage in types of inflammatory arthritis. Check with your doctor.
● Start with a low dose. Increase it in small increments every week if it doesn’t seem to be working.
● If you do not notice any relief from the symptoms, stop taking it. CBD is expensive and may not be right for you.

Benefits of CBD

● Help with Sleep Problems – CBD oil can provide consumers with many calming benefits and people with insomnia can be relieved of their insomnia.
● Reduce pain and inflammation – CBD cream can help people with problems ranging from digestive disorders to arthritis and some have even used it to relieve acne.
● Alternative to tobacco – Some people use CBD as an alternative to tobacco. However, the point is, it doesn’t cause any stimulation like nicotine.

It is important to understand that CBD is not and should not be taken as a cure for any disease or ailment that may exist. It has not been scientifically proven to hold any type of medicinal properties. These types of products should only be used as alternative products as they cannot diagnose, treat or prevent any type of disease. Find out more about Is CBD Good For Anxiety And Stress Relief see below.

For more information, please visit
https://www.indicadreams.com

https://www.youtube.com/watch?v=cne04BxjJpY

Media manager
Indica Dreams
write us here

Source link

]]>
https://heiki.org/is-cbd-good-for-anxiety-and-stress-relief/feed/ 0
Democrats push for legislation that would slow drug creation https://heiki.org/democrats-push-for-legislation-that-would-slow-drug-creation/ https://heiki.org/democrats-push-for-legislation-that-would-slow-drug-creation/#respond Thu, 22 Apr 2021 20:00:23 +0000 https://heiki.org/democrats-push-for-legislation-that-would-slow-drug-creation/ Note by opinion editor Amelia Robinson, this column appeared in the print edition of Columbus Dispatch on April 12. After a gloomy pandemic winter, Ohio fully vaccinated some 1.9 million inhabitants against Covid-19. Already everyone in the state 16 is eligible to receive a shot. Not bad, given that around this time last year, experts […]]]>


Note by opinion editor Amelia Robinson, this column appeared in the print edition of Columbus Dispatch on April 12.

After a gloomy pandemic winter, Ohio fully vaccinated some 1.9 million inhabitants against Covid-19. Already everyone in the state 16 is eligible to receive a shot.

Not bad, given that around this time last year, experts warned that vaccines could take years to become available. Instead, drugmakers Moderna, Pfizer, and Johnson & Johnson brought their vaccines to market in less than one.

After:All Ohioans aged 16 and over are now eligible for the COVID vaccine. Here’s how to get your photo

This record deployment was no accident.

This was the direct result of billions of dollars in private sector investment, coupled with US policies that encourage the invention of drugs. Thanks to our system, American biopharmaceutical companies currently have 4,500 drugs in development, including 260 vaccines, which The United States is the world leader in medical innovation.

Today, the industry is poised to produce even more life-saving cures, but only if lawmakers protect the policies that stimulate invention. Unfortunately, this is not taken for granted. Democrats in Congress are pushing for legislation that would undermine our leadership in biotechnology.

American scientists have developed the transformation technology known as messenger RNA, or mRNA, which is the basis of several leading Covid-19 vaccines. When a vaccine is administered, the mRNA instructs cells to produce a harmless version of the virus, which triggers a immune response to fight disease.

But we only saw the beginning of the potential of mRNA. The same underlying technology could give us vaccines and therapies for a a host of other diseases, including heart disease and cancer – the two leading causes of death Ohio and across the country. In 2021, cancer will demand the lives of some 25,000 Ohioans. We cannot reduce that number in the years to come if we prevent innovation.

Measures that would seriously slow down the creation of drugs abound.

One is the “Drugs Cost Reduction Now Act”, also known as HR 3. First introduced in 2019, this sweeping bill would impose foreign price controls on the United States – and is expected to be reintroduced in a matter of weeks. This move would make it nearly impossible for pharmaceutical companies to recoup their initial research costs – let alone invest in the development of new drugs – thus delaying the creation of many new treatments.



Source link

]]>
https://heiki.org/democrats-push-for-legislation-that-would-slow-drug-creation/feed/ 0
COVID-19 raises new challenges for children with epidermolysis bullosa and their families https://heiki.org/covid-19-raises-new-challenges-for-children-with-epidermolysis-bullosa-and-their-families/ https://heiki.org/covid-19-raises-new-challenges-for-children-with-epidermolysis-bullosa-and-their-families/#respond Thu, 22 Apr 2021 20:00:00 +0000 https://heiki.org/covid-19-raises-new-challenges-for-children-with-epidermolysis-bullosa-and-their-families/ Life can be incredibly difficult when even eating lunch or turning around in the middle of the night can cause you agony. This is the reality for siblings Nur Siddiqah and Muhammad Azraqee Azny. They have a rare genetic condition called epidermolysis bullosa (EB), which some call “the worst disease you’ve never heard of”. Key […]]]>


Life can be incredibly difficult when even eating lunch or turning around in the middle of the night can cause you agony.

This is the reality for siblings Nur Siddiqah and Muhammad Azraqee Azny.

They have a rare genetic condition called epidermolysis bullosa (EB), which some call “the worst disease you’ve never heard of”.

It means the the layers of their skin are not firmly anchored together, which makes it extremely fragile.

They are prone to blisters and sores, which can be as serious as deep burns.

Siddiqah says she loves to play, but even walking can be difficult.

“I love food but can’t eat most of the time,” she says.

“I want to go to the park, but I’m afraid of getting hurt.

“I’m so scared that people will hit me and hurt me.

Azraqee, 6, agrees.

“It’s difficult, but I can also have fun,” he says.

“From consciousness comes understanding”

Azraqee and Siddiqah were diagnosed with EB shortly after their birth in Malaysia.

EB has no cure, and there are approximately 500,000 people living with some variation of the condition worldwide.

Their mother, Kida Azny, said that when Siddiqah was born she was missing most of her skin, but it took almost two days to get a diagnosis.

Even then, the hospital did not have the dressing specialist the newborn baby needed and the clinicians did not know how to properly dress his wounds.

Ms Azny and her husband Mohd Aidil Aim have taken to the internet for answers.

“It was difficult because not many people want to talk about it. That’s why I’m so committed to awareness, ”she says.

“From awareness comes understanding, and from understanding comes appropriate support.”

Ms. Azny says she doesn’t want other families to feel as lonely as she is.

“Isolation, for us, has been a long-standing problem,” she says, adding that the challenges have been compounded during the COVID-19 pandemic by restrictions, a shortage of bandages and the constant angst Azraqee and Siddiqah get sick.

The pandemic brings more challenges

Simone Baird is the National Family Support Coordinator for Debra Australia, a non-profit organization for families with EB.

Ms Baird says many of their clients, already on a “very lonely journey”, have isolated themselves during the pandemic.

Zlatko Kopecki of the University of South Australia, a researcher in skin conditions such as EB, said during the lockdown, outpatient clinics were forced to close their physical doors and offer specialized services such as online skin checks.

People with certain types of EB have an increased risk of developing a type of skin cancer called squamous cell carcinoma.

“A lot of these patients go on to develop skin cancer, so it’s very important that they end up going to pathology clinics.”

Rafeeq's birthday, four children and their father are around a smiling cake.
Azraqee and Siddiqah have EB, but not their younger siblings.(

Provided: Kida Azny

)

Dr Kopecki says there is a “significant risk” that some cancers developing in EB could have been missed because specialists have not been able to examine the skin closely.

But Ms Baird said no EB family had been denied skin checks or cancer treatment during that time.

Explore potential treatment options

There is no known cure for EB, and Dr Kopecki says the development of treatment options has been slow.

Scientists explored three different options: protein therapy, cell therapy, and gene therapy.

People with EB either lack one of the proteins that bind the layers of their skin together, or the protein itself is defective.

With protein therapy, the defective or missing protein is replaced, a method that has had some success in animal testing.

But when the study passed to people, some participants developed liver problems.

Scientists are exploring different protein therapy options to avoid this problem, and clinical trials are underway.

Cell therapy offered some relief, but it was only short-lived, says Dr. Kopecki.

This procedure involves transferring healthy cells to patients with EB, with ongoing trials using bone marrow and umbilical cord stem cells.

“Gene therapy is the most promising at the moment,” he says.

It aims to correct the genetic mutation that causes EB.

Dr Kopecki says this is an expensive and difficult treatment option to explore because each patient has a different type of mutation, which means the cost of gene therapy is high.

It also involves important regulatory and safety considerations.

Dr Kopecki and his colleagues at the University of South Australia are studying treatments to improve the healing rate of blisters.

“It won’t cure the disease, but it could improve the cure rate and, therefore, reduce any risk of infection, reduce hospital stay and improve quality of life,” he says.

“We need to provide better support and better treatment for families living with the disease.”

Mrs. Baird agrees.

Her daughter Eliza died three years ago from kidney failure, a secondary complication of EB, so Ms Baird knows full well how difficult the disease can be.

“It’s the worst disease you’ve never heard of,” she says.

EB in Australia

About 1,000 people in Australia are living with EB.

Ms Baird says there are only around 160 families in the Debra database, so there are likely hundreds of people living with the disease in Australia that the organization does not know.

Ms Baird says there is a lot of support for EB patients in the pediatric system, but not enough for adults.

“Once the transition starts to happen from the pediatric system to the adult system… they fall through the cracks,” she says.

“[People with EB] tend to set themselves apart as they get older in life, with skin cancer and complications, [and] they require more care with hospitalizations. “

Dr Kopecki says there is also a need for more specialist EB nurses across Australia.

“Right now there are four specialist EB nurses: one in Sydney, Melbourne, Adelaide and Brisbane,” he says.

‘Scared’ to return to Malaysia

Azraqee and Siddiqah have two younger siblings, Muhammad Rafeeq, two, and Nur Saqeenah, three months, both born in Australia and neither of them have EB.

The family moved to Australia in 2017 to participate in a clinical trial and hope to stay, but are still awaiting news of their residency application.

Azraqee and Siddiqah are riding bikes on the street and looking at the camera.
Azraqee and Siddiqah need daily care for their condition.(

Provided: Kida Azny

)

Ms Azny says she is afraid to leave Australia, where the standard of care is higher.

Siddiqah and Azraqee go to a mainstream school in Australia, which is not possible for them in their home country due to a lack of specialist support.

Siddiqah wants to become an arts and crafts teacher when she grows up. it’s one of his favorite classes at school.

And Azraqee says he wants to be a policeman, because he “would like to ride in a car with the siren on”.





Source link

]]>
https://heiki.org/covid-19-raises-new-challenges-for-children-with-epidermolysis-bullosa-and-their-families/feed/ 0